Neurofibroma with increased uptake of [F-18]-fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion

Annals of Nuclear Medicine

Volumn 17, Issue 7, 2003, Pages 609-611

  Hsu, Chung Huei ^a   Lee, Chi Ming ^a   Wang, Fong Chieh ^a   Fang, Chia Lang ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

FDG; Neurofibroma; PET

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; NEUROFIBROMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECTUM CARCINOMA; SPINAL CORD; SPINDLE CELL; THORAX RADIOGRAPHY;

EID: 0242661373     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03006677     Document Type: Article

References (16)

1. Cook GJ, Fogelman I, Maisey MN, et al. Normal physiological and pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26: 308-314.
2. Ferner RE, O'Doherty MJ. Neurofibroma and schwannoma. Curr Opin Neurol 2002; 15: 679-684.
3. Khong PL, Goh WH, Wong VC, Fung CW, Ooi GC. MR imaging of spinal tumors in children with neurofibromatosis 1. AJR 2003; 180: 413-417.
4. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32: 47-59.
5. Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, et al. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Aun Nucl Med 1996; 10: 185-191.
6. Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109: 982-988.
7. Yang SN, Liang JA, Lin FJ, Kwan AS, Kao CH, Shen YY. Differentiating benign and malignant pulmonary lesions with FDG-PET. Anticancer Res 2001; 21: 4153-4157.
8. Hsu WH, Hsu NY, Shen YY, Yen RF, Kao CH. Differentiating solitary pulmonary metastases in patients with extrapulmonary neoplasms using FDG-PET. Cancer Invest 2003; 21: 47-52.
9. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003; 44: 717-724.
10. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 2003; 32: 133-138.
11. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42: 713-720.
12. Gabriel M, Erler H, Donnemiller E, Riccabona G. Increased F-18 fluorodeoxyglucose accumulation in a benign neurofibroma-a pitfall in a patient with thyroid cancer: a case report. Nuklearmedizin 2002; 41: N14-15.
13. Kubota K, Yamada S, Kondo T, Yamada K, Fukuda H, Fujiwara T, et al. PET imaging of primary mediastinal tumors. Br J Cancer 1996; 73: 882-886.
14. Ahmed AR, Watanabe H, Aoki J, Shinozaki T, Takagishi K. Schwannoma of the extremities: the role of PET in preoperative planning. Eur J Nucl Med 2001; 928: 1541-1551.
15. Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, et al. Evaluation of (18)fluorodeoxy-glucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000; 68: 353-35.
16. Solomon SB, Dogan AS, Nicol TL, Campbell JN, Pomper MG. Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis. Clin Nucl Med 2001; 26: 525-526.